| Ytd | -4.48% | |
| 1y | 376.67% |
| Open | 5.86 | Prev Close | 5.90 | Low | 5.00 | High | 6.01 | Mkt Cap | 474.88M |
| Vol | 1.68M | Avg Vol | 1.02M | EPS | -1.09 | P/E | N/A | Forward P/E | -3.22 |
| Beta | 0.14 | Short Ratio | 14.48 | Inst. Own | 58.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 4.51 | 200-d Avg | 4.75 | 1yr Est | 14.29 |
Tibulizumab is the first and only bispecific antibody targeting both BAFF and IL-17 in clinical deve
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotech